Technical Analysis for TPTX - Turning Point Therapeutics, Inc.

Grade Last Price % Change Price Change
grade A 40.97 1.46% 0.59
TPTX closed up 1.46 percent on Friday, May 24, 2019, on 54 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong N/A N/A Up
See historical TPTX trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Doji - Bearish? Reversal 0.00%
New 52 Week High Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Multiple of Ten Bullish Other 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%

Older signals for TPTX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients, and is planned to enter a registrational Phase 2 study in the second half of 2019. Turning Point’s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Medicine Cancer Chemical Compounds Treatment Of Cancer Oncology Solid Tumors Non Small Cell Lung Cancer Antineoplastic Drugs Cancer Treatment Targeted Therapy Cancer Therapies Pyrrolidines Signal Transduction Protein Kinase Inhibitors Kinase
Is TPTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 41.0144
52 Week Low 24.21
Average Volume 201,700
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 34.3335
10-Day Moving Average 35.193
Average True Range 2.6207
ADX 54.15
+DI 34.2283
-DI 6.935
Chandelier Exit (Long, 3 ATRs ) 33.1523
Chandelier Exit (Short, 3 ATRs ) 35.5621
Upper Bollinger Band 40.3592
Lower Bollinger Band 28.3078
Percent B (%b) 1.05
BandWidth 35.100995
MACD Line 2.6987
MACD Signal Line 1.5747
MACD Histogram 1.124
Fundamentals Value
Market Cap 661.82 Million
Num Shares 16.2 Million
EPS -1.33
Price-to-Earnings (P/E) Ratio -30.83
Price-to-Sales 0.85
Price-to-Book 1.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 42.66
Resistance 3 (R3) 42.48 41.75 42.38
Resistance 2 (R2) 41.75 41.32 41.84 42.28
Resistance 1 (R1) 41.36 41.05 41.55 41.53 42.19
Pivot Point 40.62 40.62 40.72 40.71 40.62
Support 1 (S1) 40.24 40.20 40.43 40.41 39.75
Support 2 (S2) 39.50 39.93 39.59 39.66
Support 3 (S3) 39.11 39.50 39.56
Support 4 (S4) 39.28